Representations and Warranties in Biotech M&A

Introduction

Representations and warranties (R&W) are contractual assurances made by the seller, founders, or target company during a merger or acquisition. They describe the target’s legal, financial, operational, and regulatory condition. In biotechnology mergers and acquisitions (M&A), these assurances are especially important because the value of a company may depend on patents, clinical-trial data, regulatory approvals, biological materials, manufacturing quality, and intellectual property.

A representation is generally a statement of fact that induces a party to enter into a contract, while a warranty is a contractual promise whose breach may give rise to damages. Indian law does not comprehensively codify this distinction for M&A transactions; the agreement’s wording and the Indian Contract Act, 1872, are therefore important.

lawsikho.com+1

Biotech-Specific Representations and Warranties

In a biotech acquisition, the seller should provide carefully drafted assurances concerning:

Intellectual property: Ownership and validity of patents, licences, trade secrets, and freedom to operate.

Clinical-trial integrity: Accuracy of trial data, informed consent, ethics approvals, and disclosure of adverse events.

Regulatory compliance: Validity of drug approvals, manufacturing licences, and compliance with applicable rules.

Product safety: Known defects, recalls, contamination, and product-liability claims.

Research materials: Lawful ownership and use of biological samples, genetic data, and research materials.

These warranties should be supported by due diligence, disclosure schedules, and specific indemnities for known risks. A buyer should not rely on general assurances where a material defect has already been identified.

All Chapters+1

Important Case Laws

1. Avitel Post Studioz Ltd. v. HSBC PI Holdings (Mauritius) Ltd., (2020) 4 SCC 1

HSBC invested in Avitel based on representations about a major BBC contract. It later alleged that the contract was fictitious and that the investment had been induced by fraud. The Supreme Court held that the allegations involved fraudulent inducement under Sections 17 and 18 of the Indian Contract Act and supported interim protection in the arbitration dispute.

The case demonstrates that material false representations in an investment agreement can result in substantial contractual and arbitral consequences. It is not a biotech case, but its principles apply to false assurances about clinical partnerships, licensing deals, or a target’s pipeline value.

Indian Kanoon+1

2. GWL Properties Ltd. v. James Mackintosh & Co. Pvt. Ltd., Bombay High Court, Arbitration Petition No. 272 of 2010

The dispute concerned contractual warranties in a commercial transaction. The case is cited for the importance of clear drafting and interpretation of the warranty language agreed by the parties. It supports the principle that courts and arbitral tribunals must examine the actual contractual wording rather than assume that every statement made during negotiations constitutes a warranty.

International Bar Association

3. Satyabrata Ghose v. Mugneeram Bangur & Co., AIR 1954 SC 44

The Supreme Court explained the operation of contractual obligations and the doctrine of frustration under Section 56 of the Indian Contract Act. Although not an M&A warranty case, it is relevant where a biotech transaction depends on a regulatory approval or event that later becomes impossible.

The case does not excuse a seller from a false warranty. It instead illustrates the need to distinguish an inaccurate existing fact from a later event affecting performance.

Economic Laws Practice

Conclusion

Representations and warranties are essential risk-allocation tools in biotech M&A. They enable buyers to assess the reliability of a target’s science, regulatory position, intellectual property, and commercial prospects. Under Indian law, false statements may trigger remedies under Sections 17–19 of the Indian Contract Act, while breach of contractual warranties may lead to damages or agreed indemnification.

The cases discussed provide general contractual guidance; there is no established Indian Supreme Court precedent specifically defining biotech M&A warranties. Accordingly, parties should use precise drafting, specialist due diligence, and tailored indemnities to protect against risks involving clinical data, patents, product safety, and regulatory compliance.